Compare Illumina, Inc. (ILMN) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Sanofi SA — how do they compare? Illumina, Inc. trades at $192.8 (market cap $27.94B), while Sanofi SA trades at $44.05 (market cap $104.83B). The key difference: Sanofi SA is far larger — about 3.8× Illumina, Inc.'s market cap, and Sanofi SA pays a 5.5% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | SNY | |
|---|---|---|
Market Cap | $27.94B | $104.83B |
Sector | Health | Health |
52-Week High | $194.33 | $52.34 |
52-Week Low | $91.00 | $41.33 |
Enterprise Value | $29.33B | $121.32B |
Dividend Yield | — | 5.5% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
